Doxorubicin-cisplatin-vinblastine combination chemotherapy of advanced endometrial carcinoma: A Southwest Oncology Group study

David S Alberts, Nancy L. Mason, Robert V. O'Toole, Robert D. Hilgers, Saul E. Rivkin, John G. Boutselis, Reginald P. Pugh, Vainutis K. Vaitkevicius, J. Benjamin Green, Noburu Oishi

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

A combination of doxorubicin (30 mg/m2 iv), cisplatin (50 mg/m2 iv), and vinblastine (5 mg/m2 iv) repeated every 3-4 weeks was used to treat 55 patients with advanced stage III or IV or recurrent disease. Of the 42 fully evaluable patients, there were 3 complete responders (7%) and 10 partial responders (24%). Responses were of short duration (median of 8 months, range 3-15 months) and the median survival of all evaluable patients was only 10 months from the start of therapy. Leukopenia was the major toxicity and was at least moderate in two-thirds of patients. We conclude that the addition of cisplatin and vinblastine to doxorubicin does not improve the clinical utility of doxorubicin in patients with advanced endometrial cancer.

Original languageEnglish (US)
Pages (from-to)193-201
Number of pages9
JournalGynecologic Oncology
Volume26
Issue number2
DOIs
StatePublished - 1987

Fingerprint

Vinblastine
Endometrial Neoplasms
Combination Drug Therapy
Doxorubicin
Cisplatin
Leukopenia
Survival

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Doxorubicin-cisplatin-vinblastine combination chemotherapy of advanced endometrial carcinoma : A Southwest Oncology Group study. / Alberts, David S; Mason, Nancy L.; O'Toole, Robert V.; Hilgers, Robert D.; Rivkin, Saul E.; Boutselis, John G.; Pugh, Reginald P.; Vaitkevicius, Vainutis K.; Green, J. Benjamin; Oishi, Noburu.

In: Gynecologic Oncology, Vol. 26, No. 2, 1987, p. 193-201.

Research output: Contribution to journalArticle

Alberts, DS, Mason, NL, O'Toole, RV, Hilgers, RD, Rivkin, SE, Boutselis, JG, Pugh, RP, Vaitkevicius, VK, Green, JB & Oishi, N 1987, 'Doxorubicin-cisplatin-vinblastine combination chemotherapy of advanced endometrial carcinoma: A Southwest Oncology Group study', Gynecologic Oncology, vol. 26, no. 2, pp. 193-201. https://doi.org/10.1016/0090-8258(87)90273-3
Alberts, David S ; Mason, Nancy L. ; O'Toole, Robert V. ; Hilgers, Robert D. ; Rivkin, Saul E. ; Boutselis, John G. ; Pugh, Reginald P. ; Vaitkevicius, Vainutis K. ; Green, J. Benjamin ; Oishi, Noburu. / Doxorubicin-cisplatin-vinblastine combination chemotherapy of advanced endometrial carcinoma : A Southwest Oncology Group study. In: Gynecologic Oncology. 1987 ; Vol. 26, No. 2. pp. 193-201.
@article{9ab90376a25847fd8a0166932543bca8,
title = "Doxorubicin-cisplatin-vinblastine combination chemotherapy of advanced endometrial carcinoma: A Southwest Oncology Group study",
abstract = "A combination of doxorubicin (30 mg/m2 iv), cisplatin (50 mg/m2 iv), and vinblastine (5 mg/m2 iv) repeated every 3-4 weeks was used to treat 55 patients with advanced stage III or IV or recurrent disease. Of the 42 fully evaluable patients, there were 3 complete responders (7{\%}) and 10 partial responders (24{\%}). Responses were of short duration (median of 8 months, range 3-15 months) and the median survival of all evaluable patients was only 10 months from the start of therapy. Leukopenia was the major toxicity and was at least moderate in two-thirds of patients. We conclude that the addition of cisplatin and vinblastine to doxorubicin does not improve the clinical utility of doxorubicin in patients with advanced endometrial cancer.",
author = "Alberts, {David S} and Mason, {Nancy L.} and O'Toole, {Robert V.} and Hilgers, {Robert D.} and Rivkin, {Saul E.} and Boutselis, {John G.} and Pugh, {Reginald P.} and Vaitkevicius, {Vainutis K.} and Green, {J. Benjamin} and Noburu Oishi",
year = "1987",
doi = "10.1016/0090-8258(87)90273-3",
language = "English (US)",
volume = "26",
pages = "193--201",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Doxorubicin-cisplatin-vinblastine combination chemotherapy of advanced endometrial carcinoma

T2 - A Southwest Oncology Group study

AU - Alberts, David S

AU - Mason, Nancy L.

AU - O'Toole, Robert V.

AU - Hilgers, Robert D.

AU - Rivkin, Saul E.

AU - Boutselis, John G.

AU - Pugh, Reginald P.

AU - Vaitkevicius, Vainutis K.

AU - Green, J. Benjamin

AU - Oishi, Noburu

PY - 1987

Y1 - 1987

N2 - A combination of doxorubicin (30 mg/m2 iv), cisplatin (50 mg/m2 iv), and vinblastine (5 mg/m2 iv) repeated every 3-4 weeks was used to treat 55 patients with advanced stage III or IV or recurrent disease. Of the 42 fully evaluable patients, there were 3 complete responders (7%) and 10 partial responders (24%). Responses were of short duration (median of 8 months, range 3-15 months) and the median survival of all evaluable patients was only 10 months from the start of therapy. Leukopenia was the major toxicity and was at least moderate in two-thirds of patients. We conclude that the addition of cisplatin and vinblastine to doxorubicin does not improve the clinical utility of doxorubicin in patients with advanced endometrial cancer.

AB - A combination of doxorubicin (30 mg/m2 iv), cisplatin (50 mg/m2 iv), and vinblastine (5 mg/m2 iv) repeated every 3-4 weeks was used to treat 55 patients with advanced stage III or IV or recurrent disease. Of the 42 fully evaluable patients, there were 3 complete responders (7%) and 10 partial responders (24%). Responses were of short duration (median of 8 months, range 3-15 months) and the median survival of all evaluable patients was only 10 months from the start of therapy. Leukopenia was the major toxicity and was at least moderate in two-thirds of patients. We conclude that the addition of cisplatin and vinblastine to doxorubicin does not improve the clinical utility of doxorubicin in patients with advanced endometrial cancer.

UR - http://www.scopus.com/inward/record.url?scp=0023117229&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023117229&partnerID=8YFLogxK

U2 - 10.1016/0090-8258(87)90273-3

DO - 10.1016/0090-8258(87)90273-3

M3 - Article

C2 - 3542743

AN - SCOPUS:0023117229

VL - 26

SP - 193

EP - 201

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -